Pharmacotherapy and non

Create a study schedule and stick to it. Allocate time for reading, writing, listening, speaking, and problem-solving exercises every day. #生活技巧# #英语学习#

Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Conflict of interest statement

Declaration of interests XM has received personal fees from Allergan-AbbVie, Aptis Pharma, Biogen, BMS, Grünenthal, Haute Autorité de Santé, Lilly, Lundbeck, Teva, Merck-Serono, Novartis, Orion, Pfizer, Roche, and Sanofi-Genzyme; grants from APICIL, region Auvergne-Rhone-Alpes, contrat Interface Inserm; and non-financial support from SOS Oxygène, unrelated to the submitted work. DCdA reports being vice-chair, research committee of the European Federation of IASP chapters, section editor European Journal of Pain, and being on the advisory board Pain Reports; is an employee of Aalborg Universitet, Denmark; is a non-remunerated collaborator professor of the University of Sao Paulo, Brazil; received institutional investigator-initiated research grants from Cristalia, Mundipharma, Saint Jude–Abbott Medical, Medtronic, Magventure, Grunenthal; gave remunerated lectures for Mundipharma, GreenCare, and Magventure; received conference travel support from the Pain Center University of Sao Paulo, Brazil, and Megventure; received a research grant from Fundacao de Amparo à Pesquisa do Estado de Sao Paulo, Brazil), the Novo Nordisk Foundation, Neuroscience Academy Denmark (Lundbeck Foundation), Horizon Europe (Fresco4NoPain European consortium), and the EU European Research Council. RB has financial interest of affiliation with the following organisations that could be perceived as a real or apparent competing interest. Grant or research support: EU Projects: Europain (115007); DOLORisk (633491) and IMI Paincare (777500); German Federal Ministry of Education and Research, Verbundprojekt—Frühdetektion von Schmerzchronifizierung (NoChro) (13GW0338C); German Research Network on Neuropathic Pain (01EM0903); Pfizer Pharma, Grünenthal GmbH, Mundipharma Research, Alnylam Pharmaceuticals, Zambon, Sanofi Aventis GmbH, Viatris; Speaker: Pfizer Pharma, Sanofi Aventis, Grünenthal, Mundipharma, Lilly, Desitin Arzneimittel, Teva, Bayer, MSD, Seqirus Australia, Novartis Pharma, TAD Pharma, Grünenthal Portugal, Grünen-thal Pharma Schweiz, Grünenthal Niederlande, Evapharma, Takeda Pharmaceuticals International Schweiz, Ology Medical Education Netherlands, Ever Pharma, Amicus Therapeutics, Novo Nordisk Pharma, Chiesi, Stada Mena Dubai, Hexal, Viatris, AstraZeneca, and Sandoz. Consultant: Pfizer Pharma, Sanofi Aventis, Grünenthal, Lilly, Novartis Pharma, Bristol-Myers Squibb, Biogenidec, AstraZeneca, Daiichi Sankyo, Glenmark Pharmaceuticals, Seqirus Australia, Teva Pharmaceuticals Europe Niederlande, Teva, Genentech, Mundipharma International, Galapagos, Kyowa Kirin, Vertex Pharmaceuticals, Biotest, Celgene, Desitin Arzneimittel, Regeneron Pharmaceuticals USA, Theranexus Frankreich, Abbott Products Operations Schweiz, Bayer, Grünenthal Pharma Schweiz, Akcea Therapeutics Germany, Asahi Kasei Pharma, AbbVie Deutschland, Air Liquide Sante International Frankreich, Alnylam Germany, Lateral Pharma, Hexal, Angelini, Janssen, SIMR Biotech Australia, Confo Therapeutics Belgium, Merz Pharmaceuticals, Neumentum, F Hoffmann-La Roche Switzerland, AlgoTherapeutix France, Nanobiotix France, AmacaThera Canada, Heat2Move, Resano, Esteve Pharmaceuticals, Aristo, Viatris. DLHB has been a consultant for 5 am ventures, AditumBio, Astra Zeneca, Biogen, Biointervene, Combigene, LatigoBio, GSK, Ionis, Lexicon therapeutics, Neuvati, Novo Ventures, Olipass, Orion, Replay, SC Health Managers, Third Rock ventures, and Vida Ventures, Vertex on behalf of Oxford University Innovation; has received research funding from Lilly and Astra Zeneca; has received an industrial partnership grant from the BBSRC and AstraZeneca; has received funding from EU Projects: “Europain” (115007) and DOLORisk (633491); and has received funding from Wellcome Trust, the Medical Research Council, Versus Arthritis and Diabetes UK. IG has received support from Vertex and Combigene, and has received grants from the Canadian Institutes of Health Research, Physicians’ Services Incorporated Foundation, and Queen's University. EM declares no competing interests. AJH has received lecture fees from Sanofi, Teva, Takeda, Merck, Pfizer, Lundbeck, CSL Behring, Fresenius Kabi, Alexion Pharmaceuticals, MSD, Otsuka Pharmaceutical, and Novartis Finland. He has received research funding from Alnylam and Sanofi-Genzyme. He has acted as a consultant for Sanofi and Takeda. KH has received lecture fees, consulting fees, and contract research funds from Daiichi Sankyo, lecture fees from Medtronic Japan, Boston Scientific Japan, Nippon Zoki Pharmaceutical, and Mikasa Seiyaku, consulting fees from Teijin Pharma, Araya, and the Japanese Society of Psychiatry and Neurology, travel expenses from Integra Japan, and grants from the Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, and Taiju Life Social Welfare Foundation. HK has received funding from the National Institute for Health & Care Research, UK for a Clinical Lectureship (Feb, 2019–Jan, 2024) and the Academy of Medical Sciences for unrelated projects. EKE-K holds an endowed professorship funded by the German Social Accident Insurance for a period of 6 years and has received intramural funding from the Medical Faculty of the Ruhr University Bochum (grant number IF-031-22), from the Georg Agricola Ruhr Foundation as well as from the Bundesministerium für Wirtschaft und Technologie (grant number 50WK2273B) and has also received personal fees from Novartis, Casquar GmbH, OmegaPharma, and painCert. TJP is a co-founder of 4E Therapeutics, PARMedics, Nerveli, NuvoNuro, and Doloromics. He has received consulting fees from GSK, ADARx, Grunenthal, and Gordian. He holds or has held research grants or contracts with Hoba Therapeutics, Bellus Health, Merck, Eli Lilly, Evommune, Abbvie, and National Institutes of Health, USA. SNR is a consultant for Abbvie and Vertex. ASCR declares the following (last 36 months): Officer of IASP; employee of Imperial College London; consultancy for Imperial College Consultants- has included remunerated work for: Astra Zeneca, Pharmnovo, Confo, Combigene, and Shanghai SIMR Biotech & Science Practice (Wellcome Trust); inventor on patents WO 2005/079771 & EP13702262.0/ WO2013 110945. Member Joint Committee on Vaccine and Immunisation—varicella sub-committee; Analgesic Clinical Trial Translation: Innovations, Opportunities, and Networks steering committee member. Medicines and Healthcare products Regulatory Agency, Commission on Human Medicines—Neurology, Pain & Psychiatry Expert Advisory Group. Grants and studentships—UK Research and Innovation (Medical Research Council and Biotechnology and Biological Sciences Research Council), Versus Arthritis, Alan and Sheila Diamond Trust, Royal British Legion, European Commission, Ministry of Defence, Dr Jennie Gwynn Bequests, The British Pain Society, Royal Society of Medicine Lecture honoraria (some donated to charity); MD Cancer Center, University California San Francisco; BIOEVENTS, Royal Marsden Hospital, Indonesian Neurological Association Pain Study Group International Lecture Series, Malaysian Society of Anaesthesiologists, Siriraj Hospital (Bangkok), Pain Association of Singapore, Hospital for Special Surgery (New York). DH-S has received grant funding from the Alan and Sheila Diamond Charitable Trust, The Society for Back Pain Research, and Chelsea and Westminster Hospital Joint Research Council; and consultancy fees from Altern Health for unrelated projects. BHS has received, on behalf of his institution, research funding from Eli Lilly, unrelated to the submitted work. AT has acted as a consultant for Amgen, Viatris, Angelini Pharma, Grunenthal GmbH; he has received research funding from Angelini Pharma and Epitech and has received funding from the EU Project IMI-PainCare (777500). JV has received research funding or consultancy fees from Viatris, AstraZeneca, and Merz, unrelated to the submitted work. JDW is a fellow of the Berlin Institute of Health (BIH) Charité Digital Clinician Scientist (DCSP) Program funded by the DFG, the Charité—Universitätsmedizin Berlin, and the BIH at Charité; he received travel funding by the BIH DCSP Mobility Funds and the German Pain Society (Deutsche Schmerzgesellschaft). NA has received personal fees from Grunenthal, UPSA, Pfizer, Merz, Medtronic, Novartis, Viatris outside the submitted work and is member of the Dolorisk, HaPPy and Fresco4Pain European consortia. NBF has received consultancy fees from PharmNovo, Vertex, NeuroPN, Saniona, Nanobiotix, and Neurvati, and has done consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics; she has received grants from IMI2PainCare an EU IMI 2 (Innovative medicines initiative) and the companies involved are Grunenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work. SH has received research grants from the US National Institutes of Health and Department of Defense, as well as from Eli Lilly, outside the submitted work. He has received consultancy fees from Vertex. NS, MCF, RAA, JB, MC, PD, ME, SF, BG, PRK, GTK, EW, JP, HP, CRP, TIPi, AR, FT, NT-L, QVT, CW, AZ, and MDZ have no competing interests to declare.

网址：Pharmacotherapy and non https://klqsh.com/news/view/207406

相关内容

Chronic pain: an update on burden, best practices, and new advances
Commentary: A Citizenship without Social Rights? EU Freedom of Movement and Changing Access to Welfare Rights
Zip and unzip files
Cm To Feet And Inches Calculator – Instant Conversion – This to That Calculator
Jawan OTT Details: Streaming Partner and Time, Rights.
Animal Testing Facts and Statistics
Tickets and Hours
500 Important Synonyms and Antonyms (+ Example Sentences)
Molecular and cellular insights into T cell exhaustion
Renault : un dérapage non contrôlé

随便看看